Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 17,001 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ELEVATE Clear all
Completed No phase listed Observational Accepts healthy volunteers

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

NCT00900055
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Fanconi Anemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
microarray analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, chromatography, high performance liquid chromatography, immunoenzyme technique
Genetic · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
1 Year to 55 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1975 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 25, 2026, 9:03 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Multisite Prevention of Conduct Problems (Fast Track)

NCT01653535
View directory record Official record
Conditions
Conduct Disorder, Anti-Social Behavior
Interventions
Fast Track
Behavioral
Lead sponsor
Duke University
Other
Eligibility
6 Years to 8 Years
Enrollment
891 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 25, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

NCT01913535
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
CERC-501, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Chicago, Illinois • Wichita, Kansas • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 9:03 PM EDT
Not listed Phase 4 Interventional

The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study

NCT01323608
View directory record Official record
Conditions
Thalassemia Major
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
6 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 25, 2026, 9:03 PM EDT
Active, not recruiting No phase listed Observational

OCS™ Lung TOP Registry For Donor Lungs for Transplantation

NCT03639025
View directory record Official record
Conditions
Lung Transplantation
Interventions
OCS Lung System
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 25, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

NCT00303940
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
carboplatin, talabostat mesylate, temozolomide, pharmacological study
Drug · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
2 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 25, 2026, 9:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET

NCT01719497
View directory record Official record
Conditions
Obesity, Alcohol Dependence, High Stress
Interventions
[C-11]OMAR
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 25, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Results available

Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial

NCT01294358
View directory record Official record
Conditions
Histologically or Cytologically Confirmed Pancreatic Ca, Unresectable or Borderline Resectable Pancreatic Ca
Interventions
Gemcitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 25, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

NCT02293148
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 25, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study

NCT00288626
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Granulocyte-colony stimulating factor (G-CSF) and prednisone, Carmustine, etoposide, cytarabine, and melphalan (BEAM), Autologous hematopoietic stem cell transplant
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
4
States / cities
Columbus, Ohio • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 25, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

BEhavioral EConomics for Oral Health iNnovation Trial

NCT03576326
View directory record Official record
Conditions
Toothbrushing, Dental Plaque, Parent-Child Relations, Oral Hygiene, Dental Caries
Interventions
Drawing Incentive
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Months to 47 Months
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 25, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

HIS-Purkinje Conduction System Pacing Optimized Trial of Cardiac Resynchronization Therapy

NCT04561778
View directory record Official record
Conditions
Heart Failure，Congestive, Cardiomyopathies, Left Ventricular Dysfunction
Interventions
HOT-CRT, Biventricular Pacing
Device
Lead sponsor
Pugazhendhi Vijayaraman
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 25, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glycemic Index and CVD: a Crossover Feeding Study

NCT00141076
View directory record Official record
Conditions
Obesity
Interventions
low vs high glycemic index diet
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Oct 25, 2026, 9:03 PM EDT
Terminated No phase listed Observational

Effectiveness of Manual Physical Therapy to Improve Endocrine Levels in Women

NCT02027168
View directory record Official record
Conditions
FSH Hypersecretion, Endocrine System Diseases, Infertility
Interventions
CPA
Other
Lead sponsor
Clear Passage Therapies, Inc
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 25, 2026, 9:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Gamification in an Online Grocery Store.

NCT04919668
View directory record Official record
Conditions
Food Selection, Food Preferences, Behavior, Eating
Interventions
Simulated grocery shopping exercise
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
1,185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 25, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02207491
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 25, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer

NCT00470574
View directory record Official record
Conditions
Breast Cancer
Interventions
QS21, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine, immunoenzyme technique, immunologic technique, laboratory biomarker analysis
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 25, 2026, 9:03 PM EDT
Withdrawn Early Phase 1 Interventional

Androgen Regulation of Priapism in Sickle Cell Disease

NCT01940718
View directory record Official record
Conditions
Priapism, Sickle Cell Disease, Hypogonadism
Interventions
Transdermal Androgel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 25, 2026, 9:03 PM EDT
Withdrawn Phase 2 Interventional

StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies

NCT02765997
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia
Interventions
Unmanipulated UCB, SR-1 UCB
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 25, 2026, 9:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps

NCT06376565
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Best Practice, Communication Intervention, Interview
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
1,680 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 25, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional

Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

NCT06206564
View directory record Official record
Conditions
Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN
Interventions
Artesunate ointment, Placebo
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 25, 2026, 9:03 PM EDT
Recruiting No phase listed Observational

Cognitive and Vascular Functioning Following TBI

NCT06034509
View directory record Official record
Conditions
Traumatic Brain Injury, Cognitive Decline, Vascular Dementia
Interventions
No intervention. This is an observational study.
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 74 Years
Enrollment
300 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 25, 2026, 9:03 PM EDT
Withdrawn Phase 1 Interventional

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

NCT00659399
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Fondaparinux
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 25, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

NCT03146416
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evinacumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 25, 2026, 9:03 PM EDT